Intrinsic value of Repligen - RGEN

Previous Close

$61.86

  Intrinsic Value

$0.68

stock screener

  Rating & Target

str. sell

-99%

Previous close

$61.86

 
Intrinsic value

$0.68

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of RGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  47.10
  42.89
  39.10
  35.69
  32.62
  29.86
  27.37
  25.14
  23.12
  21.31
  19.68
  18.21
  16.89
  15.70
  14.63
  13.67
  12.80
  12.02
  11.32
  10.69
  10.12
  9.61
  9.15
  8.73
  8.36
  8.02
  7.72
  7.45
  7.20
  6.98
Revenue, $m
  208
  297
  413
  560
  743
  965
  1,229
  1,538
  1,894
  2,297
  2,749
  3,250
  3,799
  4,396
  5,039
  5,727
  6,461
  7,237
  8,057
  8,918
  9,820
  10,763
  11,748
  12,773
  13,841
  14,951
  16,106
  17,305
  18,552
  19,847
Variable operating expenses, $m
  147
  190
  246
  317
  405
  512
  639
  788
  960
  1,154
  1,325
  1,566
  1,830
  2,118
  2,427
  2,759
  3,112
  3,487
  3,881
  4,296
  4,731
  5,185
  5,659
  6,153
  6,668
  7,203
  7,759
  8,337
  8,937
  9,561
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  147
  190
  246
  317
  405
  512
  639
  788
  960
  1,154
  1,325
  1,566
  1,830
  2,118
  2,427
  2,759
  3,112
  3,487
  3,881
  4,296
  4,731
  5,185
  5,659
  6,153
  6,668
  7,203
  7,759
  8,337
  8,937
  9,561
Operating income, $m
  60
  107
  167
  243
  338
  453
  590
  750
  934
  1,143
  1,425
  1,684
  1,969
  2,278
  2,611
  2,968
  3,348
  3,751
  4,175
  4,622
  5,089
  5,578
  6,088
  6,620
  7,173
  7,749
  8,347
  8,968
  9,614
  10,286
EBITDA, $m
  116
  166
  230
  313
  415
  538
  686
  858
  1,056
  1,282
  1,534
  1,813
  2,119
  2,452
  2,811
  3,195
  3,604
  4,037
  4,494
  4,974
  5,478
  6,004
  6,553
  7,125
  7,721
  8,340
  8,984
  9,653
  10,349
  11,071
Interest expense (income), $m
  0
  7
  11
  18
  26
  36
  49
  65
  84
  106
  131
  160
  192
  227
  266
  309
  354
  403
  455
  510
  569
  630
  694
  761
  831
  904
  979
  1,058
  1,140
  1,225
  1,314
Earnings before tax, $m
  54
  95
  149
  217
  302
  404
  525
  666
  829
  1,012
  1,265
  1,493
  1,742
  2,012
  2,303
  2,614
  2,945
  3,295
  3,665
  4,053
  4,459
  4,884
  5,327
  5,789
  6,270
  6,769
  7,288
  7,828
  8,389
  8,972
Tax expense, $m
  15
  26
  40
  59
  81
  109
  142
  180
  224
  273
  342
  403
  470
  543
  622
  706
  795
  890
  990
  1,094
  1,204
  1,319
  1,438
  1,563
  1,693
  1,828
  1,968
  2,114
  2,265
  2,422
Net income, $m
  39
  70
  109
  159
  220
  295
  383
  486
  605
  739
  924
  1,090
  1,271
  1,469
  1,681
  1,908
  2,150
  2,406
  2,675
  2,959
  3,255
  3,565
  3,889
  4,226
  4,577
  4,941
  5,321
  5,715
  6,124
  6,549

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  877
  1,253
  1,742
  2,364
  3,136
  4,072
  5,186
  6,490
  7,991
  9,694
  11,601
  13,714
  16,030
  18,547
  21,261
  24,167
  27,260
  30,537
  33,994
  37,627
  41,434
  45,414
  49,568
  53,896
  58,400
  63,086
  67,956
  73,017
  78,277
  83,743
Adjusted assets (=assets-cash), $m
  877
  1,253
  1,742
  2,364
  3,136
  4,072
  5,186
  6,490
  7,991
  9,694
  11,601
  13,714
  16,030
  18,547
  21,261
  24,167
  27,260
  30,537
  33,994
  37,627
  41,434
  45,414
  49,568
  53,896
  58,400
  63,086
  67,956
  73,017
  78,277
  83,743
Revenue / Adjusted assets
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
Average production assets, $m
  234
  335
  466
  632
  838
  1,089
  1,386
  1,735
  2,136
  2,591
  3,101
  3,666
  4,285
  4,958
  5,684
  6,461
  7,288
  8,164
  9,088
  10,059
  11,077
  12,141
  13,251
  14,408
  15,613
  16,865
  18,167
  19,520
  20,926
  22,388
Working capital, $m
  65
  92
  128
  174
  231
  300
  382
  478
  589
  714
  855
  1,011
  1,182
  1,367
  1,567
  1,781
  2,009
  2,251
  2,506
  2,773
  3,054
  3,347
  3,653
  3,972
  4,305
  4,650
  5,009
  5,382
  5,770
  6,172
Total debt, $m
  171
  267
  392
  550
  747
  986
  1,270
  1,602
  1,985
  2,419
  2,906
  3,444
  4,035
  4,677
  5,369
  6,110
  6,899
  7,734
  8,616
  9,542
  10,513
  11,528
  12,587
  13,691
  14,839
  16,034
  17,276
  18,567
  19,908
  21,302
Total liabilities, $m
  224
  319
  444
  603
  800
  1,038
  1,323
  1,655
  2,038
  2,472
  2,958
  3,497
  4,088
  4,730
  5,421
  6,162
  6,951
  7,787
  8,668
  9,595
  10,566
  11,581
  12,640
  13,743
  14,892
  16,087
  17,329
  18,619
  19,961
  21,354
Total equity, $m
  653
  933
  1,298
  1,761
  2,336
  3,033
  3,864
  4,835
  5,953
  7,222
  8,643
  10,217
  11,942
  13,818
  15,839
  18,004
  20,309
  22,750
  25,325
  28,032
  30,868
  33,834
  36,928
  40,152
  43,508
  46,999
  50,627
  54,398
  58,316
  62,389
Total liabilities and equity, $m
  877
  1,252
  1,742
  2,364
  3,136
  4,071
  5,187
  6,490
  7,991
  9,694
  11,601
  13,714
  16,030
  18,548
  21,260
  24,166
  27,260
  30,537
  33,993
  37,627
  41,434
  45,415
  49,568
  53,895
  58,400
  63,086
  67,956
  73,017
  78,277
  83,743
Debt-to-equity ratio
  0.260
  0.290
  0.300
  0.310
  0.320
  0.320
  0.330
  0.330
  0.330
  0.330
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
Adjusted equity ratio
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  39
  70
  109
  159
  220
  295
  383
  486
  605
  739
  924
  1,090
  1,271
  1,469
  1,681
  1,908
  2,150
  2,406
  2,675
  2,959
  3,255
  3,565
  3,889
  4,226
  4,577
  4,941
  5,321
  5,715
  6,124
  6,549
Depreciation, amort., depletion, $m
  55
  59
  64
  69
  77
  85
  96
  108
  122
  138
  109
  129
  150
  174
  199
  227
  256
  286
  319
  353
  389
  426
  465
  506
  548
  592
  637
  685
  734
  786
Funds from operations, $m
  95
  129
  172
  228
  297
  380
  479
  594
  727
  877
  1,032
  1,218
  1,422
  1,643
  1,880
  2,135
  2,406
  2,692
  2,994
  3,312
  3,644
  3,991
  4,354
  4,732
  5,125
  5,533
  5,958
  6,400
  6,858
  7,335
Change in working capital, $m
  21
  28
  36
  46
  57
  69
  82
  96
  111
  126
  141
  156
  171
  186
  200
  214
  228
  242
  255
  268
  281
  293
  306
  319
  332
  345
  359
  373
  388
  403
Cash from operations, $m
  74
  101
  136
  182
  240
  311
  397
  498
  616
  752
  892
  1,063
  1,251
  1,457
  1,680
  1,921
  2,178
  2,451
  2,739
  3,044
  3,363
  3,698
  4,048
  4,413
  4,793
  5,188
  5,599
  6,026
  6,471
  6,932
Maintenance CAPEX, $m
  -6
  -8
  -12
  -16
  -22
  -29
  -38
  -49
  -61
  -75
  -91
  -109
  -129
  -150
  -174
  -199
  -227
  -256
  -286
  -319
  -353
  -389
  -426
  -465
  -506
  -548
  -592
  -637
  -685
  -734
New CAPEX, $m
  -75
  -101
  -131
  -166
  -206
  -250
  -298
  -349
  -401
  -455
  -510
  -565
  -619
  -673
  -725
  -777
  -827
  -876
  -924
  -971
  -1,018
  -1,064
  -1,110
  -1,157
  -1,204
  -1,252
  -1,302
  -1,353
  -1,406
  -1,461
Cash from investing activities, $m
  -81
  -109
  -143
  -182
  -228
  -279
  -336
  -398
  -462
  -530
  -601
  -674
  -748
  -823
  -899
  -976
  -1,054
  -1,132
  -1,210
  -1,290
  -1,371
  -1,453
  -1,536
  -1,622
  -1,710
  -1,800
  -1,894
  -1,990
  -2,091
  -2,195
Free cash flow, $m
  -7
  -8
  -6
  0
  12
  31
  61
  101
  154
  221
  291
  389
  503
  634
  781
  944
  1,124
  1,319
  1,529
  1,754
  1,993
  2,245
  2,511
  2,791
  3,083
  3,388
  3,705
  4,036
  4,380
  4,737
Issuance/(repayment) of debt, $m
  72
  96
  125
  159
  197
  239
  284
  332
  383
  434
  486
  539
  591
  642
  692
  741
  789
  836
  881
  926
  971
  1,015
  1,059
  1,104
  1,149
  1,195
  1,242
  1,291
  1,341
  1,394
Issuance/(repurchase) of shares, $m
  171
  210
  256
  305
  354
  403
  447
  485
  513
  530
  498
  484
  454
  407
  341
  257
  155
  36
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  243
  306
  381
  464
  551
  642
  731
  817
  896
  964
  984
  1,023
  1,045
  1,049
  1,033
  998
  944
  872
  881
  926
  971
  1,015
  1,059
  1,104
  1,149
  1,195
  1,242
  1,291
  1,341
  1,394
Total cash flow (excl. dividends), $m
  235
  298
  375
  463
  563
  673
  792
  918
  1,050
  1,185
  1,275
  1,412
  1,548
  1,682
  1,814
  1,942
  2,068
  2,190
  2,410
  2,680
  2,963
  3,260
  3,571
  3,894
  4,231
  4,582
  4,947
  5,327
  5,721
  6,130
Retained Cash Flow (-), $m
  -210
  -280
  -365
  -463
  -575
  -698
  -830
  -971
  -1,118
  -1,269
  -1,421
  -1,574
  -1,726
  -1,875
  -2,022
  -2,165
  -2,305
  -2,441
  -2,575
  -2,707
  -2,836
  -2,965
  -3,094
  -3,224
  -3,356
  -3,490
  -3,628
  -3,771
  -3,918
  -4,072
Prev. year cash balance distribution, $m
  149
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  174
  18
  10
  0
  -12
  -25
  -38
  -53
  -68
  -83
  -146
  -162
  -178
  -193
  -208
  -223
  -237
  -251
  -165
  -26
  127
  295
  476
  670
  875
  1,092
  1,319
  1,556
  1,802
  2,058
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  167
  17
  8
  0
  -9
  -18
  -26
  -33
  -39
  -44
  -69
  -69
  -68
  -65
  -61
  -57
  -52
  -46
  -25
  -3
  13
  24
  31
  34
  34
  32
  28
  24
  20
  15
Current shareholders' claim on cash, %
  92.2
  86.1
  81.3
  77.3
  74.0
  71.3
  69.1
  67.3
  65.7
  64.5
  63.5
  62.8
  62.2
  61.7
  61.4
  61.1
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0
  61.0

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

FINANCIAL RATIOS  of  Repligen (RGEN)

Valuation Ratios
P/E Ratio 174.4
Price to Sales 19.9
Price to Book 12.4
Price to Tangible Book
Price to Cash Flow 261.7
Price to Free Cash Flow 523.3
Growth Rates
Sales Growth Rate 25%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 33.3%
Cap. Spend. - 3 Yr. Gr. Rate -4.4%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 56.2%
Total Debt to Equity 56.2%
Interest Coverage 0
Management Effectiveness
Return On Assets 5.5%
Ret/ On Assets - 3 Yr. Avg. 6.2%
Return On Total Capital 6.2%
Ret/ On T. Cap. - 3 Yr. Avg. 7.1%
Return On Equity 8.2%
Return On Equity - 3 Yr. Avg. 7.8%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 54.3%
Gross Margin - 3 Yr. Avg. 55.9%
EBITDA Margin 16.2%
EBITDA Margin - 3 Yr. Avg. 20.4%
Operating Margin 15.2%
Oper. Margin - 3 Yr. Avg. 16.4%
Pre-Tax Margin 11.4%
Pre-Tax Margin - 3 Yr. Avg. 14.7%
Net Profit Margin 11.4%
Net Profit Margin - 3 Yr. Avg. 11.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 19.3%
Payout Ratio 0%

RGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RGEN stock intrinsic value calculation we used $141.236 million for the last fiscal year's total revenue generated by Repligen. The default revenue input number comes from 0001 income statement of Repligen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RGEN stock valuation model: a) initial revenue growth rate of 47.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RGEN is calculated based on our internal credit rating of Repligen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Repligen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RGEN stock the variable cost ratio is equal to 81.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for RGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.6% for Repligen.

Corporate tax rate of 27% is the nominal tax rate for Repligen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RGEN are equal to 112.8%.

Life of production assets of 28.5 years is the average useful life of capital assets used in Repligen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RGEN is equal to 31.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $591.548 million for Repligen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.694 million for Repligen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Repligen at the current share price and the inputted number of shares is $2.7 billion.

RELATED COMPANIES Price Int.Val. Rating
TECH Bio-Techne 157.53 89.32  str.sell
BMRN BioMarin Pharm 92.34 2.96  str.sell
TMO Thermo Fisher 237.50 199.97  hold

COMPANY NEWS

▶ Trump Trade Comments Boost Dow Jones; These 6 Growth Stocks Take Market Helm   [Nov-16-18 02:15PM  Investor's Business Daily]
▶ Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018   [Nov-09-18 01:25PM  Investor's Business Daily]
▶ 3 Growth Stocks for In-the-Know Investors   [Nov-04-18 06:49PM  Motley Fool]
▶ IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook   [Nov-01-18 04:19PM  Investor's Business Daily]
▶ Repligen: 3Q Earnings Snapshot   [08:09AM  Associated Press]
▶ Repligen to Report Third Quarter 2018 Financial Results   [Oct-22-18 07:30AM  GlobeNewswire]
▶ Repligen Corporation (NASDAQ:RGEN): Earnings To Drop Next Year   [Oct-05-18 08:49AM  Simply Wall St.]
▶ Repligen (RGEN) Misses Q2 Earnings Estimates   [Aug-02-18 12:55PM  Zacks]
▶ Repligen: 2Q Earnings Snapshot   [11:49AM  Associated Press]
▶ Repligen to Report Second Quarter 2018 Financial Results   [Jul-19-18 11:48AM  GlobeNewswire]
▶ CVS will offer home delivery of prescriptions   [Jun-19-18 01:25PM  Yahoo Finance Video]
▶ Moving Average Crossover Alert: Repligen (RGEN)   [May-23-18 07:34AM  Zacks]
▶ Repligen: 1Q Earnings Snapshot   [May-08-18 07:59AM  Associated Press]
▶ Repligen to Report First Quarter 2018 Financial Results   [Apr-30-18 11:00AM  GlobeNewswire]
▶ 3 Top Growth Stocks to Buy Right Now   [Apr-26-18 10:50AM  Motley Fool]
▶ 3 Top Stocks You Can Buy and Hold for the Next Decade   [Apr-24-18 07:47AM  Motley Fool]
▶ My Investing Horror Story: Selling Too Early   [Apr-12-18 06:33AM  Motley Fool]
▶ Repligen beats Street 4Q forecasts   [Feb-22-18 08:43AM  Associated Press]
▶ 3 Growth Stocks to Buy for 2018   [Dec-20-17 06:34AM  Motley Fool]
▶ Top 3 Healthcare Penny Stocks for 2017   [Dec-10-17 03:59PM  Investopedia]
▶ 3 Growth Stocks to Buy and Hold for 25 Years   [Dec-07-17 09:00AM  Motley Fool]
▶ 3 Bioeconomy Stocks That Have a Killer Advantage   [Nov-29-17 09:16AM  Motley Fool]
▶ Repligen tops Street 3Q forecasts   [07:43AM  Associated Press]
▶ Top 3 Healthcare Penny Stocks for 2017   [Nov-08-17 12:20PM  Investopedia]
▶ ETFs with exposure to Repligen Corp. : November 1, 2017   [Nov-01-17 12:36PM  Capital Cube]
▶ Stocks With Rising Relative Strength: Repligen   [Oct-31-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to Repligen Corp. : October 20, 2017   [Oct-20-17 10:24AM  Capital Cube]
▶ ETFs with exposure to Repligen Corp. : October 9, 2017   [Oct-09-17 11:59AM  Capital Cube]
▶ ETFs with exposure to Repligen Corp. : September 28, 2017   [Sep-28-17 10:19AM  Capital Cube]
▶ Repligen Announces Analyst Day and Webcast   [Sep-15-17 07:30AM  GlobeNewswire]
▶ Repligen beats Street 2Q forecasts   [Aug-03-17 06:26PM  Associated Press]
▶ Repligen beats Street 2Q forecasts   [10:43AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.